MedTrace Logo

Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

NCT00848523 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2010-07-16

No results posted yet for this study

Summary

The drug LBH589 (panobinostat) is an experimental (investigational) drug that is being tested for recurrent (returning) malignant gliomas. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). It belongs to a new class of drugs called "histone deacetylase inhibitors." Histones are proteins located in the nucleus of cells that bind to DNA, the chemical that makes up genes. These proteins help control which genes are turned "on" and "off." Studies have shown that drugs like panobinostat (LBH589) may lead to tumor cell death.

Conditions

  • Recurrent Malignant Gliomas

Interventions

DRUG

Panobinostat

30 mg, three times a week, patients will continue with treatment until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.

Sponsors & Collaborators

  • Neurological Surgery, P.C.

    lead OTHER

Principal Investigators

  • J. Paul Duic, MD · Long Island Brain Tumor Center at Neurological Surgery PC / Long Island Neuro-Oncology Associates

  • Jai Grewal, MD · Long Island Brain Tumor Center at Neurological Surgery PC/ Long Island Neuro-oncology Associates

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00848523 on ClinicalTrials.gov